CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial
Click here to view our proxy materials for the meeting to be held on August 20, 2014:
CytoDyn Investment Community Call to Discuss Interim Results from its Treatment Substitution Study in Patients with HIV
©2014 CytoDyn Inc. All Rights Reserved.
Website by Equisolve
The next class of antiviral agents for the treatment of HIV